Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Kimyrsa vs Orbactiv in ABSSSI
NCT03873987Phase 1Completed
- Sponsor
- Melinta Therapeutics
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of oritavancin in acute bacterial skin and skin structure infection (ABSSSI) (2 arms), sponsored by Melinta Therapeutics. Primary endpoints: Relative Exposure of AUC of the New Formulation to the Approved Formulation (Timeframe: 72 hours) and Relative Exposure of AUC of the New Formulation to the Approved Formulation (Timeframe: 168 hours (Day 8)). Started Jul 2019; status: completed.
02
Drugs
oritavancin
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT03873987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873987.